Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 Combined With Chemotherapy in First-line Advanced NSCLC
NCT06969027Phase 2Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of JS207 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Objective Response Rate at 25 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
JS207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06969027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969027.